D. E. Shaw & Co., Inc. Outlook Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
Shares
3 transactions
Others Institutions Holding OTLK
# of Institutions
7Shares Held
67.1KCall Options Held
0Put Options Held
0-
Prospera Financial Services Inc30.5KShares$223,2600.0% of portfolio
-
Endurance Wealth Management, Inc.20KShares$146,4000.0% of portfolio
-
Urban Wealth Management, LLC7.47KShares$54,7020.03% of portfolio
-
American Portfolios Advisors Holbrook, NY4KShares$29,2800.0% of portfolio
-
Armstrong Advisory Group, Inc Needham, MA3.58KShares$26,2050.0% of portfolio
About Outlook Therapeutics, Inc.
- Ticker OTLK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 226,144,992
- Market Cap $1.66B
- Description
- Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...